In the study, which was published recently in Multiple SclerosisJournal, the authors noted that the tolerability and effects of dalfampridine-ER in clinical practice had not previously been reported.1

For the study, all patients at the Portland VAMC prescribed dalfampridine-ER over one year completed the Timed 25-Foot Walk (T25FW), Multiple Sclerosis Walking Scale-12 (MSWS-12), Two-Minute Timed Walk (2MTW) and Community Integration Questionnaire (CIQ) at baseline and follow-up clinic visits. Ongoing use and measures were then analyzed.

The 39 participants averaged 56.5 years old and were 82% male. Their mean disease duration was 20 years, with 38% having relapsing-remitting MS and 62% progressive MS.

“Dalfampridine-ER was associated with short-term improvements in walking speed and community participation, and sustained improvements in walking endurance and self-perceived impact of MS on walking for one year,” the authors concluded. “Our study supports the utility of this medication in late MS.”